Pharmaceuticals

With booming revenue, a potential blockbuster on the horizon, and key partnerships, Ascendis Pharma lays out a bold roadmap for global dominance.

With drug costs soaring, industry veteran Ritu Malhotra joins Illuminate Rx, promising to disrupt the opaque PBM market. But can transparency truly win?

After a decade of research, a promising drug for Fragile X syndrome enters a key trial, offering hope for the first-ever targeted treatment for the disorder.

Beyond a simple time change, Fortrea's upcoming JPM presentation is a critical test for its new CEO and a key moment to define its future in the CRO market.

A novel drug that glues cancer proteins to the cellular trash system has entered human trials, offering new hope for rare diseases like Ewing sarcoma.

Promising Phase 2 data shows a new DNA immunotherapy for advanced melanoma, delivered via a needle-free jet injector, significantly improves patient outcomes.

As part of a $23B US investment, Novartis will build a cutting-edge facility in Winter Park, cementing Florida’s role in advanced cancer treatment.

Amazon Pharmacy now offers the new Wegovy pill with transparent cash-pay options, shaking up the high-demand weight management drug market.

Automated Industrial Robotics Inc. acquires Ireland's KAON Automation, a strategic move to dominate the high-stakes medical and life sciences market.

After resolving manufacturing hurdles, Camurus' self-administered acromegaly treatment Oclaiz is back on track for US approval, promising new hope for patients.

Prescient's acquisition of Uptake creates an integrated giant in healthcare consulting. What does this mean for the industry, clients, and patient outcomes?

Akari Therapeutics is advancing a new class of cancer drugs. Its unique PH1 payload kills tumors and activates the immune system, setting up a pivotal 2026.

Health Canada uncovers counterfeit erectile dysfunction drugs in Mississauga, warning of life-threatening dangers and a compromised supply chain.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

With its first MASH drug a success, Madrigal aims to redefine treatment by combining it with a newly licensed Pfizer asset. Is this the future?

A validated study on LEON's FR-JET® mixer shows it creates highly concentrated, potent mRNA nanoparticles, promising to speed up drug development.

Aesthetics firm Evolus reports its first profitable quarter and robust growth, banking on new products and international markets to defy industry slowdowns.

With a key drug in late-stage trials and a bolstered team, Palvella Therapeutics aims to deliver the first FDA-approved therapies for rare skin diseases.

As Mammoth Biosciences preps for JPM, its ultracompact CRISPR tech aims to redefine in vivo gene therapy, promising cures for diseases beyond the liver.

Riding a 50% revenue surge, Rhythm Pharmaceuticals faces a pivotal year with a major FDA decision and key clinical data for its rare obesity treatments.